Y.D. More Investments Ltd Invests $84,000 in Bristol-Myers Squibb (NYSE:BMY)

Y.D. More Investments Ltd purchased a new position in Bristol-Myers Squibb (NYSE:BMY) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,027 shares of the biopharmaceutical company’s stock, valued at approximately $84,000.

Several other institutional investors and hedge funds also recently bought and sold shares of BMY. Gryphon Financial Partners LLC lifted its position in Bristol-Myers Squibb by 23.5% during the fourth quarter. Gryphon Financial Partners LLC now owns 5,235 shares of the biopharmaceutical company’s stock valued at $280,000 after purchasing an additional 995 shares in the last quarter. Foundations Investment Advisors LLC lifted its position in Bristol-Myers Squibb by 10.0% during the fourth quarter. Foundations Investment Advisors LLC now owns 58,514 shares of the biopharmaceutical company’s stock valued at $2,848,000 after purchasing an additional 5,315 shares in the last quarter. Haverford Trust Co lifted its position in Bristol-Myers Squibb by 2.0% during the fourth quarter. Haverford Trust Co now owns 78,241 shares of the biopharmaceutical company’s stock valued at $4,015,000 after purchasing an additional 1,518 shares in the last quarter. Fiera Capital Corp purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at $508,000. Finally, Atlantic Edge Private Wealth Management LLC purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at $67,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Trading Down 0.7 %

Shares of BMY stock opened at $48.25 on Friday. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $60.58. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. The stock’s 50 day simple moving average is $46.60 and its two-hundred day simple moving average is $46.54. The company has a market cap of $97.80 billion, a PE ratio of -15.56, a price-to-earnings-growth ratio of 12.62 and a beta of 0.46.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business had revenue of $12.20 billion for the quarter, compared to the consensus estimate of $11.54 billion. During the same period in the prior year, the business posted $1.75 earnings per share. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. Research analysts predict that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.97%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. TD Cowen raised their price target on Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a “hold” rating in a report on Monday, August 12th. Barclays raised their price target on Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an “underweight” rating in a report on Thursday, August 22nd. Jefferies Financial Group raised their price target on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a report on Wednesday, August 28th. Cantor Fitzgerald reissued a “neutral” rating and set a $45.00 price target on shares of Bristol-Myers Squibb in a report on Monday, July 22nd. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $54.67.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.